Bellevue Group Ag Intellia Therapeutics, Inc. Transaction History

Bellevue Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $791,761 - $1.05 Million	14,684 Added 92.97%	30,478 $1.71 Million
Q2 2022 Aug 11, 2022	SELL	$38.49 - $76.21 $19,245 - $38,105	-500 Reduced 3.07%	15,794 $817,000
Q1 2022 May 13, 2022	SELL	$58.27 - $118.99 $17,481 - $35,697	-300 Reduced 1.81%	16,294 $1.18 Million
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $2.2 Million - $2.93 Million	16,594 New	16,594 $2.23 Million
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $202,516 - $278,995	-15,834 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$11.39 - $27.13 $6,834 - $16,278	-600 Reduced 3.65%	15,834 $216,000
Q3 2018 Nov 13, 2018	SELL	$25.78 - $32.6 $7,734 - $9,780	-300 Reduced 1.79%	16,434 $470,000
Q2 2018 Aug 07, 2018	BUY	$20.02 - $30.79 $335,014 - $515,239	16,734 New	16,734 $458,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.